The current study, published recently in Journal of Immunotherapy for Cancer, evaluated outcomes for 201 patients with mRCC who were treated with ICIs at Winship Cancer Institute from 2015 through ...

Julia Choy, MD, of Barts Cancer Institute in London, UK, and colleagues identified 112 patients with mRCC who underwent a deferred CN at a median 111.5 days following treatment with the targeted ...